Should MDS patients get chemo before a stem cell transplant? new trial aims to find out.

NCT ID NCT06918834

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two strategies for people with higher-risk myelodysplastic syndrome (MDS): getting a donor stem cell transplant right away versus receiving one to two cycles of chemotherapy first (called bridging therapy) before the transplant. The goal is to see if immediate transplant is at least as good as the pre-treatment approach. About 236 adults will take part, and the main outcome is how many are alive and cancer-free two years after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

allogeneic hematopoietic stem cell transplantation (a donor stem cell transplant) with or without pre-transplant chemotherapy (azacitidine, venetoclax, or targeted drugs)

What this could lead to

If it works, this could show that going straight to transplant is just as effective as pre-treatment, potentially simplifying care and reducing side effects for higher-risk MDS patients.

What could go wrong

This is a Phase 2 trial with 236 participants, so results are still early. The study may not prove one approach is clearly better, and stem cell transplants carry serious risks like infection and graft-versus-host disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijin, Beijing Municipality, 100044, China

    Contact

  • People's Liberation Army The General Hospital of Western Theater Command

    RECRUITING

    Chengdu, Sichuan, 610083, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army

    RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-••••

  • The Second Hospital of Hebei Medical University

    RECRUITING

    Shijia Zhuang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhengzhou University First Affiliated Hospital

    RECRUITING

    Zhengzhou, Henan, 450000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••